These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 7662242

  • 1. Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension.
    Dahlöf B, Keller SE, Makris L, Goldberg AI, Sweet CS, Lim NY.
    Am J Hypertens; 1995 Jun; 8(6):578-83. PubMed ID: 7662242
    [Abstract] [Full Text] [Related]

  • 2. Losartan potassium as initial therapy in patients with severe hypertension.
    Dunlay MC, Fitzpatrick V, Chrysant S, Francischetti EA, Goldberg AI, Sweet CS.
    J Hum Hypertens; 1995 Nov; 9(11):861-7. PubMed ID: 8583463
    [Abstract] [Full Text] [Related]

  • 3. Randomised, double-blind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension.
    Chan JC, Critchley JA, Lappe JT, Raskin SJ, Snavely D, Goldberg AI, Sweet CS.
    J Hum Hypertens; 1995 Sep; 9(9):765-71. PubMed ID: 8551492
    [Abstract] [Full Text] [Related]

  • 4. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components.
    MacKay JH, Arcuri KE, Goldberg AI, Snapinn SM, Sweet CS.
    Arch Intern Med; 1996 Feb 12; 156(3):278-85. PubMed ID: 8572837
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-week extension phase in adult Korean patients with mild-to-moderate hypertension.
    Lee SE, Kim YJ, Lee HY, Yang HM, Park CG, Kim JJ, Kim SK, Rhee MY, Oh BH, Investigators.
    Clin Ther; 2012 Mar 12; 34(3):552-568, 568.e1-9. PubMed ID: 22381711
    [Abstract] [Full Text] [Related]

  • 6. Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist, in the treatment of hypertension.
    Mallion JM, Goldberg AI.
    Blood Press Suppl; 1996 Mar 12; 2():82-6. PubMed ID: 8913546
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM, Malacco E, Khder Y, Kandra A, Bönner G, Heintz D.
    Clin Ther; 2005 May 12; 27(5):578-87. PubMed ID: 15978306
    [Abstract] [Full Text] [Related]

  • 8. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
    Dahlöf B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, Julius S, Kjeldsen S, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H.
    Am J Hypertens; 1997 Jul 12; 10(7 Pt 1):705-13. PubMed ID: 9234823
    [Abstract] [Full Text] [Related]

  • 9. The clinical efficacy and tolerability of the angiotensin II-receptor antagonist losartan in Japanese patients with hypertension.
    Ogihara T, Yoshinaga K.
    Blood Press Suppl; 1996 Jul 12; 2():78-81. PubMed ID: 8913545
    [Abstract] [Full Text] [Related]

  • 10. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
    Devereux RB, de Faire U, Fyhrquist F, Harris KE, Ibsen H, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Hille DA, Dahlöf B.
    Curr Med Res Opin; 2007 Feb 12; 23(2):259-70. PubMed ID: 17288679
    [Abstract] [Full Text] [Related]

  • 11. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T, Smith TR, Glazer R, Wernsing M, Yen J, Jin J, Schneider H, Pospiech R.
    Clin Ther; 2007 Apr 12; 29(4):563-80. PubMed ID: 17617280
    [Abstract] [Full Text] [Related]

  • 12. Results of a phase III, 8-week, multicenter, prospective, randomized, double-blind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension.
    Kim SH, Kim YD, Lim DS, Yoon MH, Ahn YK, On YK, Lee JW, Kim IJ, Park JB, Kim JJ, Chung WS, Yang JY, Seo HS, Shin EK, Kim HS, Korean Multicenter Amlodipine Study Investigators.
    Clin Ther; 2007 Sep 12; 29(9):1924-36. PubMed ID: 18035192
    [Abstract] [Full Text] [Related]

  • 13. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
    Poldermans D, Glazes R, Kargiannis S, Wernsing M, Kaczor J, Chiang YT, Yen J, Gamboa R, Fomina I.
    Clin Ther; 2007 Feb 12; 29(2):279-89. PubMed ID: 17472820
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of losartan.
    Goldberg A, Sweet C.
    Can J Cardiol; 1995 Aug 12; 11 Suppl F():27F-32F. PubMed ID: 7664215
    [Abstract] [Full Text] [Related]

  • 15. Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension.
    Weir MR, Elkins M, Liss C, Vrecenak AJ, Barr E, Edelman JM.
    Clin Ther; 1996 Aug 12; 18(3):411-28. PubMed ID: 8829017
    [Abstract] [Full Text] [Related]

  • 16. A multicenter, randomized, double-blind, parallel-group trial of the antihypertensive efficacy and tolerability of a combination of once-daily losartan 100 mg/hydrochlorothiazide 12.5 mg compared with losartan 100-mg monotherapy in the treatment of mild to severe essential hypertension.
    Gleim GW, Rubino J, Zhang H, Shahinfar S, Soffer BA, Lyle PA, Littlejohn TW, Feig PU.
    Clin Ther; 2006 Oct 12; 28(10):1639-48. PubMed ID: 17157119
    [Abstract] [Full Text] [Related]

  • 17. [Efficacy and safety of olmesartan medoxomil versus losartan potassium in Chinese patients with mild to moderate essential hypertension].
    Zhu JR, Cai NS, Fan WH, Zhu DL, He B, Wu ZG, Ke YN, Guo JX, Ma H, Huang J, Li XL, Chen YZ.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Oct 12; 34(10):877-81. PubMed ID: 17217710
    [Abstract] [Full Text] [Related]

  • 18. Long-term effects of losartan on blood pressure and left ventricular structure in essential hypertension.
    Himmelmann A, Svensson A, Bergbrant A, Hansson L.
    J Hum Hypertens; 1996 Nov 12; 10(11):729-34. PubMed ID: 9004102
    [Abstract] [Full Text] [Related]

  • 19. A randomised, double-blind, double-dummy comparison of the efficacy and tolerability of lercanidipine tablets and losartan tablets in patients with mild to moderate essential hypertension.
    James IG, Jones A, Davies P.
    J Hum Hypertens; 2002 Aug 12; 16(8):605-10. PubMed ID: 12149668
    [Abstract] [Full Text] [Related]

  • 20. Efficacy, tolerability, and effects on quality of life of losartan, alone or with hydrochlorothiazide, versus amlodipine, alone or with hydrochlorothiazide, in patients with essential hypertension.
    Oparil S, Barr E, Elkins M, Liss C, Vrecenak A, Edelman J.
    Clin Ther; 1996 Aug 12; 18(4):608-25. PubMed ID: 8879890
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.